GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » Debt-to-Revenue

Apex Biotechnology (TPE:1733) Debt-to-Revenue : 0.09 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Apex Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$45 Mil. Apex Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$116 Mil. Apex Biotechnology's annualized Revenue for the quarter that ended in Mar. 2024 was NT$1,803 Mil. Apex Biotechnology's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.09.


Apex Biotechnology Debt-to-Revenue Historical Data

The historical data trend for Apex Biotechnology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology Debt-to-Revenue Chart

Apex Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.29 0.16 0.11 0.11

Apex Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.10 0.09 0.11 0.09

Competitive Comparison of Apex Biotechnology's Debt-to-Revenue

For the Biotechnology subindustry, Apex Biotechnology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Debt-to-Revenue falls into.



Apex Biotechnology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Apex Biotechnology's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(64.635 + 116.196) / 1676.537
=0.11

Apex Biotechnology's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(44.756 + 115.83) / 1802.632
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Apex Biotechnology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Apex Biotechnology (TPE:1733) Business Description

Traded in Other Exchanges
N/A
Address
No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines